Table 2 Initial treatment, salvage therapy and outcome of 6 R/R ALAL-NOS patients
No. | Previous treatment | Reinduction treatment | VEN dose, (mg) | VEN days | Response to VEN combination | HSCT | Outcome | OS(m) |
|---|---|---|---|---|---|---|---|---|
1 | Chemotherapy and HSCT | VEN + AZA | 400 mg | 28d | CR | N | Dead | 36 |
2 | VDCP NR; DAC + HACVP NR | VEN + AAVP | 400 mg | 14d | CR | Y | CR | 15 |
3 | VDCP NR; DAC + HACVP NR | VEN + AAVP PR; DAC + VEN + AAVP | 400 mg | 21d | CR | Y | Dead | 9 |
4 | DAC + AAVP NR | VEN + HOAP | 200 mg (with voriconazole) | 14d | CRi | Y | CR | 8 |
5 | VDCP + AA NR | VEN + CA | 400 mg | 14d | CR | Y | CR | 7 |
6 | AACVP NR | VEN + HOAP | 400 mg | 14d | CR | Y | CR | 5 |